scholarly journals ‘Vidangadi Lauha’ for Obese Type 2 Diabetes mellitus; Randomized controlled clinical study

2021 ◽  
Author(s):  
Punam Khobarkar ◽  
Jayant Gulhane ◽  
Amit Nakanekar
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Study ◽  
Targeted Treatment ◽  
High Density Lipoproteins ◽  
Control Group ◽  
Randomized Controlled ◽  
Controlled Clinical Study

Abstract Type 2 Diabetes mellitus in obese persons is becoming threatening disease due to increasing prevalence of its microvascular and macro vascular complications. A multi targeted treatment can be considered better over single targeted treatment; in view of multiple pathways involved in pathogenesis of diabetes and its complications. This open labelled randomized controlled clinical Study was aimed to evaluate clinical efficacy of ‘Vidangadi Lauha’(An Ayurveda formulation) in comparison with metformin for obese type II diabetes mellitus. Participants were divided into two groups. Trial group received Vidangadi Lauha 5gm BID and control group received tablet metformin 500mg BID for duration of 3 months. Among 550 screened participants 120 participants were eligible, out of them 100 participants were enrolled and randomized by computer generated method, out of them 80 patients (40 in each group) completed the trial. Both the treatments were equally effective in reducing blood sugar fasting(F), post meal(PM) glycated Haemoglobin (HbA1C) and Body Mass Index (BMI). Vidangadi Lauha is more effective in reducing Ayurvedic Symptoms, waist hip ratio and cholesterol as compared to Metformin. High Density Lipoproteins (HDL) were improved by minor clinical difference in both the groups. Both the treatment does not have statistically significant effect in reducing Low Density Lipoproteins (LDL).

scholarly journals Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Jing Huang ◽  
Shuyuan Xiong ◽  
Shenglan Ding ◽  
Qingfeng Cheng ◽  
Zhiping Liu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Conventional Therapy ◽  
Meta Analysis ◽  
Control Group ◽  
Controlled Trials ◽  
Randomized Controlled

Aims. To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods. Methods. We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020. A total of six studies involving 4120 patients were included. Results. Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of genital mycotic infections (GMIs) at 26 weeks ( p < 0.0001 and p < 0.0001 , respectively), 52 weeks ( p < 0.00001 and p < 0.0001 , respectively), and 104 weeks ( p < 0.00001 and p < 0.0001 , respectively). Moreover, females had a higher risk of GMIs than males in the 15 mg group at 26 weeks ( p = 0.0008 ), 52 weeks ( p < 0.0001 ), and 104 weeks ( p = 0.02 ). At 104 weeks, 15 mg and 5 mg of ertugliflozin showed beneficial effects on symptomatic hypoglycemia ( p < 0.00001 and p = 0.004 , respectively) compared with the effects observed in the control group. Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of drug-related adverse events at 26 weeks ( p = 0.002 and p = 0.002 , respectively); 15 mg of ertugliflozin was associated with a higher risk of discontinuation related to adverse events at 104 weeks ( p = 0.03 ). No significant differences were found in the remaining safety outcomes. Conclusion. This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.

ESTIMATION OF SERUM FERRITIN LEVELS IN TYPE 2 DIABETIC PATIENTS AND ITS RELATION WITH HbA1C LEVEL.

2019 ◽  
Vol 3 (8) ◽  
Author(s):  
Shah Namrata Vinubhai ◽  
Pardeep Agarwal ◽  
Bushra Fiza ◽  
Ramkishan Jat
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
Serum Ferritin ◽  
Inflammatory Marker ◽  
Control Group ◽  
Diabetic Patients ◽  
Positive Correlation

Background: Serum ferritin is known as an index for body iron stores also as an inflammatory marker and it is influenced by several disease. We were looking for a correlation between HbA1c and S. Ferritin in type 2 DM. Methodology: The present study a total of 150 participants were enrolled of which 100 were confirmed cases of Type 2 Diabetes Mellitus and rest 50 age and sex matched healthy subjects constituted the control group. All were screened for HbA1c, Fasting blood sugar, Post prandial blood sugar and S.Ferritin. Results: A highly significant variation and positive correlation was observed with respect to S.Ferritin and HbA1c levels. Mean S.Ferritin was high in the subgroup with poor glycemic control. Conclusion: The fasting, post prandial sugar levels, HbA1c and S.Ferritin were significantly higher in the diabetic subjects. This study shows a positive correlation between HbA1c and S. Ferritin levels. So we can conclude that in diabetic patients S. Ferritin may serve as an independent marker of poor glycemic and metabolic control. Keywords: Serum ferritin, Type 2 Diabetes Mellitus, HbA1c.

Rheumatoid Factor in Type 2 Male Diabetes Mellitus Patients in a Tertiary Care Hospital of Bangladesh

2018 ◽  
Vol 4 (2) ◽  
pp. 58-62
Author(s):  
Roksana Yeasmin ◽  
MA Muttalib ◽  
Kazi Nazneen Sultana ◽  
Nizamul Hoque Bhuiyan ◽  
Md Jamil Hasan Karami ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Rheumatoid Factor ◽  
Serum Uric Acid ◽  
Control Group ◽  
Healthy Male ◽  
Male Patients

Background: Type 2 diabetes mellitus is a chronic disease characterized by relative or absolute deficiency of insulin, resulting in glucose intolerance.Objectives: The present study was planned to see the associations of serum uric acid with positive Rheumatoid factor in type 2 male diabetes mellitus patients. Methodology: This case control study was carried out at the department of Biochemistry at Ibrahim Medical College, Dhaka, Bangladesh. The duration of the study was from June 2015 to June 2016 for a period of one year. In this present study, male patients with type 2 diabetes mellitus were taken as case group and age and sex matched healthy male were taken as control group. Rheumatoid factor was measured from the blood of all case and control group respondents. Others blood para meters were also measured for the correlation with the diabetes mellitus patients.Results: In this present study, 110 male patients presented with type 2 diabetes mellitus were recruited as case and age and sex matched healthy male were recruited as control. More rheumatoid factor positive in type 2 DM male patients with the uric acid range between 6.5 to 9.5 mg/dL. The number of patients was 5 out of total 9 rheumatoid factor positive cases. In this study serum uric acid was significantly correlated with rheumatoid factor in type 2 male diabetic patients. Rheumatoid factor positive cases were taking insulin among 9 and it was statistically significantly associated (p<0.001). Conclusion: In this study serum uric acid is significantly associated with positive rheumatoid factor in type 2 male diabetic patients.Journal of Current and Advance Medical Research 2017;4(2):58-62

Sign in / Sign up

Export Citation Format

Share Document